Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022Accesswire • 09/20/22
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/EnzastaurinAccesswire • 09/14/22
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth ConferenceAccesswire • 07/26/22
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of DirectorsAccesswire • 06/29/22
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor ConferenceAccesswire • 06/13/22
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic PrioritiesAccesswire • 05/16/22
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery TechnologyAccesswire • 04/25/22
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)Accesswire • 03/23/22
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease SummitAccesswire • 03/22/22
Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/18/22
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial ResultsAccesswire • 02/14/22
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory CatheterAccesswire • 11/23/21